MiNA Therapeutics Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Debt
- Investors
-
4
MiNA Therapeutics General Information
Description
Developer of therapeutic medicines designed to harness gene activation mechanisms through small activating RNA. The company's technology and clinical know-how help transform the therapy landscape of cancer and other severe diseases, enabling doctors and physicians to cure diseases and develop medicines that restore normal function to patients' cells.
Contact Information
Website
www.minatx.comCorporate Office
- Translation And Innovation Hub
- 84 Wood Lane
- London W12 0BZ
- England, United Kingdom
Corporate Office
- Translation And Innovation Hub
- 84 Wood Lane
- London W12 0BZ
- England, United Kingdom
MiNA Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Debt - General | Completed | Generating Revenue | ||||
| 8. Grant | 01-Jul-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 06-Jul-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 10-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 11-Sep-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 03-May-2017 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | Completed | Pre-Clinical Trials | ||||
| 2. Later Stage VC | 18-Jul-2016 | $2.26M | $8.94M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 10-Apr-2015 | $6.68M | $6.68M | Completed | Pre-Clinical Trials |
MiNA Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| N shares | ||||||||
| N shares | ||||||||
| A1 Preferred | ||||||||
| Series A Preferred | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 101,192 | $0.000140 | $23.17 | $23.17 | 1x | $23.17 | 4.33% | |
| Ordinary | 292,770 | $0.000140 | $21.44 | $21.44 | 1x | $21.44 | 12.54% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MiNA Therapeutics Comparisons
Industry
Financing
Details
MiNA Therapeutics Competitors (51)
One of MiNA Therapeutics’s 51 competitors is Ractigen Therapeutics, a Venture Capital-Backed company based in Nantong, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ractigen Therapeutics | Venture Capital-Backed | Nantong, China | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Allena Pharmaceuticals | Formerly VC-backed | Newton, MA | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA |
MiNA Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MiNA Therapeutics Patents
MiNA Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026027887-A2 | Hbg1/2-sarna compositions and methods of use | Pending | 02-Aug-2024 | ||
| WO-2026027887-A3 | Hbg1/2-sarna compositions and methods of use | Pending | 02-Aug-2024 | ||
| WO-2025224036-A1 | Chemically modified sarna compositions and methods of use | Pending | 22-Apr-2024 | ||
| WO-2025052098-A1 | Tmem173 sarna compositions and methods of use | Inactive | 08-Sep-2023 | ||
| GB-202313643-D0 | Serping1-sarna compositions and methods of use | Inactive | 07-Sep-2023 |
MiNA Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MiNA Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovate UK | Government | |||
| Lilly USA | Corporation | Minority | ||
| aMoon Fund | Venture Capital | Minority | ||
| Nxera Pharma | Corporation | Minority |
MiNA Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Mina Therapeutics Denmark | Koebenhavn Sv, Denmark | 2022 |
MiNA Therapeutics FAQs
-
When was MiNA Therapeutics founded?
MiNA Therapeutics was founded in 2008.
-
Where is MiNA Therapeutics headquartered?
MiNA Therapeutics is headquartered in London, United Kingdom.
-
What is the size of MiNA Therapeutics?
MiNA Therapeutics has 27 total employees.
-
What industry is MiNA Therapeutics in?
MiNA Therapeutics’s primary industry is Drug Discovery.
-
Is MiNA Therapeutics a private or public company?
MiNA Therapeutics is a Private company.
-
What is MiNA Therapeutics’s current revenue?
The current revenue for MiNA Therapeutics is .
-
How much funding has MiNA Therapeutics raised over time?
MiNA Therapeutics has raised $117M.
-
Who are MiNA Therapeutics’s investors?
Innovate UK, Lilly USA, aMoon Fund, and Nxera Pharma have invested in MiNA Therapeutics.
-
Who are MiNA Therapeutics’s competitors?
Ractigen Therapeutics, Genentech, Centrose, Allena Pharmaceuticals, and Immusoft are some of the 51 competitors of MiNA Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
